×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ALDX – aldeyra therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ALDX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/13
03:12 pm
aldx
Aldeyra Therapeutics, Inc. (ALDX) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry Eye Transcript [Seeking Alpha]
Neutral
Report
Aldeyra Therapeutics, Inc. (ALDX) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry Eye Transcript [Seeking Alpha]
11/13
07:28 am
aldx
Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast [Yahoo! Finance]
Medium
Report
Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast [Yahoo! Finance]
11/13
07:00 am
aldx
Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast
Medium
Report
Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast
11/11
07:01 am
aldx
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Low
Report
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
11/10
08:03 am
aldx
Aldeyra Therapeutics (NASDAQ:ALDX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $9.00 price target on the stock.
Medium
Report
Aldeyra Therapeutics (NASDAQ:ALDX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $9.00 price target on the stock.
11/6
07:00 am
aldx
Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET
Low
Report
Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET
10/28
07:01 am
aldx
Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules
Medium
Report
Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules
Date
Time
Symbol
Company Name
Action
%Chg
11/5/2025
04:16 pm
ALDX
aldeyra therapeutics, inc.
BEAT
Report
-2.4%
aldeyra therapeutics, inc.
8/7/2025
04:03 pm
ALDX
aldeyra therapeutics, inc.
BEAT
Report
1.7%
aldeyra therapeutics, inc.
5/14/2025
05:13 pm
ALDX
aldeyra therapeutics, inc.
BEAT
Report
1.9%
aldeyra therapeutics, inc.
Date
Time
Symbol
Headline
Impact
11/14
04:00 pm
aldx
Form SCHEDULE 13G/A Aldeyra Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC
Low
Report
Form SCHEDULE 13G/A Aldeyra Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC
11/13
07:01 am
aldx
Form 8-K Aldeyra Therapeutics, For: Nov 13
Medium
Report
Form 8-K Aldeyra Therapeutics, For: Nov 13
11/5
04:17 pm
aldx
Form 10-Q Aldeyra Therapeutics, For: Sep 30
Low
Report
Form 10-Q Aldeyra Therapeutics, For: Sep 30
10/28
07:00 am
aldx
Form 8-K Aldeyra Therapeutics, For: Oct 28
Medium
Report
Form 8-K Aldeyra Therapeutics, For: Oct 28
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/14
Aldeyra Announces Positive Top-Line Phase 1 Clinical Trial Results and Clinical Development Plans for ADX-629
27.8%
3/24 Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infection 22.9%
9/9 Form 4 Aldeyra Therapeutics, For: Sep 05 Filed by: McMullin David 13.9%
4/27 Form DEF 14A Aldeyra Therapeutics, For: Jun 09 13.1%
10/14 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.9%
3/26 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.0%
10/2 Form 4 Aldeyra Therapeutics, For: Sep 30 Filed by: Brady Todd C 8.1%
12/18 Form 4 Aldeyra Therapeutics, For: Dec 16 Filed by: Brady Todd C 5.9%
11/1 Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2019 Financial Results and Corporate Update 5.0%
1/15 Form 3 Aldeyra Therapeutics, For: Jan 13 Filed by: Miller-Rich Nancy 4.2%
3/24 Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infection 22.9%
9/9 Form 4 Aldeyra Therapeutics, For: Sep 05 Filed by: McMullin David 13.9%
4/27 Form DEF 14A Aldeyra Therapeutics, For: Jun 09 13.1%
10/14 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.9%
3/26 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.0%
10/2 Form 4 Aldeyra Therapeutics, For: Sep 30 Filed by: Brady Todd C 8.1%
12/18 Form 4 Aldeyra Therapeutics, For: Dec 16 Filed by: Brady Todd C 5.9%
11/1 Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2019 Financial Results and Corporate Update 5.0%
1/15 Form 3 Aldeyra Therapeutics, For: Jan 13 Filed by: Miller-Rich Nancy 4.2%
TOP News Decliners
12/3
Aldeyra Therapeutics Announces Positive Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease
-40.4%
3/24 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock. -17.8%
3/17 Form 4 Aldeyra Therapeutics, For: Mar 16 Filed by: DOUGLAS RICHARD -15.3%
3/6 Form 4/A Aldeyra Therapeutics, For: Mar 02 Filed by: Reed Joshua -15.3%
3/12 Aldeyra Therapeutics Reports Full-Year 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones -14.2%
8/14 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.5%
2/24 Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Day -7.3%
2/25 Form SC 13G Aldeyra Therapeutics, Filed by: Prosight Management, LP -7.0%
10/31 Form 8-K Aldeyra Therapeutics, For: Oct 31 -6.7%
4/30 Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First-Quarter 2020 Financial Results and Corporate Update -6.0%
3/24 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock. -17.8%
3/17 Form 4 Aldeyra Therapeutics, For: Mar 16 Filed by: DOUGLAS RICHARD -15.3%
3/6 Form 4/A Aldeyra Therapeutics, For: Mar 02 Filed by: Reed Joshua -15.3%
3/12 Aldeyra Therapeutics Reports Full-Year 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones -14.2%
8/14 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.5%
2/24 Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Day -7.3%
2/25 Form SC 13G Aldeyra Therapeutics, Filed by: Prosight Management, LP -7.0%
10/31 Form 8-K Aldeyra Therapeutics, For: Oct 31 -6.7%
4/30 Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First-Quarter 2020 Financial Results and Corporate Update -6.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: